Blood-pressure and cholesterol lowering in persons without cardiovascular disease
Elevated blood pressure and elevated low-density lipoprotein (LDL) cholesterol increase the risk of cardiovascular disease. Lowering both should reduce the risk of cardiovascular events substantially. In a trial with 2-by-2 factorial design, we randomly assigned 12,705 participants at intermed...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English English English |
| Published: |
Massachusetts Medical Society
2016
|
| Subjects: | |
| Online Access: | http://irep.iium.edu.my/50347/ http://irep.iium.edu.my/50347/ http://irep.iium.edu.my/50347/ http://irep.iium.edu.my/50347/9/Dr_Aznan_Blood-Pressure_and_Cholesterol_Lowering.pdf http://irep.iium.edu.my/50347/12/nejmoa1600177_appendix.pdf http://irep.iium.edu.my/50347/13/50347_Blood-Pressure_and_Cholesterol_Lowering_wos_scopus.pdf |
| id |
iium-50347 |
|---|---|
| recordtype |
eprints |
| spelling |
iium-503472017-01-04T21:49:22Z http://irep.iium.edu.my/50347/ Blood-pressure and cholesterol lowering in persons without cardiovascular disease Yusuf, Salim Phi, D. Lonn, Eva Pais, Prem Bosch, Jackie López‑Jaramillo, Patricio Md Aris, Mohd Aznan Mohd Shah, Azarisman Shah ., et. al R Medicine (General) RJ Pediatrics RZ Other systems of medicine Elevated blood pressure and elevated low-density lipoprotein (LDL) cholesterol increase the risk of cardiovascular disease. Lowering both should reduce the risk of cardiovascular events substantially. In a trial with 2-by-2 factorial design, we randomly assigned 12,705 participants at intermediate risk who did not have cardiovascular disease to rosuvastatin (10 mg per day) or placebo and to candesartan (16 mg per day) plus hydrochlorothiazide (12.5 mg per day) or placebo. In the analyses reported here, we compared the 3180 participants assigned to combined therapy (with rosuvastatin and the two antihypertensive agents) with the 3168 participants assigned to dual placebo. The first coprimary outcome was the composite of death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke, and the second coprimary outcome additionally included heart failure, cardiac arrest, or revascularization. The median follow-up was 5.6 years. Massachusetts Medical Society 2016-05-26 Article PeerReviewed application/pdf en http://irep.iium.edu.my/50347/9/Dr_Aznan_Blood-Pressure_and_Cholesterol_Lowering.pdf application/pdf en http://irep.iium.edu.my/50347/12/nejmoa1600177_appendix.pdf application/pdf en http://irep.iium.edu.my/50347/13/50347_Blood-Pressure_and_Cholesterol_Lowering_wos_scopus.pdf Yusuf, Salim and Phi, D. and Lonn, Eva and Pais, Prem and Bosch, Jackie and López‑Jaramillo, Patricio and Md Aris, Mohd Aznan and Mohd Shah, Azarisman Shah and ., et. al (2016) Blood-pressure and cholesterol lowering in persons without cardiovascular disease. New England Journal of Medicine, 374 (21). pp. 2032-2043. ISSN 0028-4793 E-ISSN 1533-4406 http://www.nejm.org/doi/full/10.1056/NEJMoa1600177#t=article 10.1056/NEJMoa1600177 |
| repository_type |
Digital Repository |
| institution_category |
Local University |
| institution |
International Islamic University Malaysia |
| building |
IIUM Repository |
| collection |
Online Access |
| language |
English English English |
| topic |
R Medicine (General) RJ Pediatrics RZ Other systems of medicine |
| spellingShingle |
R Medicine (General) RJ Pediatrics RZ Other systems of medicine Yusuf, Salim Phi, D. Lonn, Eva Pais, Prem Bosch, Jackie López‑Jaramillo, Patricio Md Aris, Mohd Aznan Mohd Shah, Azarisman Shah ., et. al Blood-pressure and cholesterol lowering in persons without cardiovascular disease |
| description |
Elevated blood pressure and elevated low-density lipoprotein (LDL) cholesterol
increase the risk of cardiovascular disease. Lowering both should reduce the risk
of cardiovascular events substantially.
In a trial with 2-by-2 factorial design, we randomly assigned 12,705 participants at
intermediate risk who did not have cardiovascular disease to rosuvastatin (10 mg per
day) or placebo and to candesartan (16 mg per day) plus hydrochlorothiazide (12.5 mg
per day) or placebo. In the analyses reported here, we compared the 3180 participants
assigned to combined therapy (with rosuvastatin and the two antihypertensive agents)
with the 3168 participants assigned to dual placebo. The first coprimary outcome was
the composite of death from cardiovascular causes, nonfatal myocardial infarction, or
nonfatal stroke, and the second coprimary outcome additionally included heart failure,
cardiac arrest, or revascularization. The median follow-up was 5.6 years. |
| format |
Article |
| author |
Yusuf, Salim Phi, D. Lonn, Eva Pais, Prem Bosch, Jackie López‑Jaramillo, Patricio Md Aris, Mohd Aznan Mohd Shah, Azarisman Shah ., et. al |
| author_facet |
Yusuf, Salim Phi, D. Lonn, Eva Pais, Prem Bosch, Jackie López‑Jaramillo, Patricio Md Aris, Mohd Aznan Mohd Shah, Azarisman Shah ., et. al |
| author_sort |
Yusuf, Salim |
| title |
Blood-pressure and cholesterol lowering in persons without cardiovascular disease |
| title_short |
Blood-pressure and cholesterol lowering in persons without cardiovascular disease |
| title_full |
Blood-pressure and cholesterol lowering in persons without cardiovascular disease |
| title_fullStr |
Blood-pressure and cholesterol lowering in persons without cardiovascular disease |
| title_full_unstemmed |
Blood-pressure and cholesterol lowering in persons without cardiovascular disease |
| title_sort |
blood-pressure and cholesterol lowering in persons without cardiovascular disease |
| publisher |
Massachusetts Medical Society |
| publishDate |
2016 |
| url |
http://irep.iium.edu.my/50347/ http://irep.iium.edu.my/50347/ http://irep.iium.edu.my/50347/ http://irep.iium.edu.my/50347/9/Dr_Aznan_Blood-Pressure_and_Cholesterol_Lowering.pdf http://irep.iium.edu.my/50347/12/nejmoa1600177_appendix.pdf http://irep.iium.edu.my/50347/13/50347_Blood-Pressure_and_Cholesterol_Lowering_wos_scopus.pdf |
| first_indexed |
2023-09-18T21:11:09Z |
| last_indexed |
2023-09-18T21:11:09Z |
| _version_ |
1777411261371252736 |